Head-to-head: half-life, weight loss in SURMOUNT-1 vs STEP-1 vs the SURMOUNT-5 head-to-head, side effects, dosing schedules, and 2026 cost. Cited from FDA labels and NEJM trials.
Why sensitive E2 (LC-MS/MS) is the right assay, the typical 20–40 pg/mL target, what high and low E2 actually feel like, and the cautious case for and against anastrozole on TRT.
Pentadecapeptide structure, acetate vs arginate salt forms, reconstitution math in insulin-syringe units, the real human evidence base, and the moving 2026 regulatory picture (HHS, FDA PCAC, WADA).
An honest look at low-dose semaglutide and tirzepatide — what the trial data does and doesn't say, what the pharmacology supports, and the open questions that aren't yet answered.
Lipohypertrophy, scar tissue, and absorption drift — what happens when you keep hitting the same site, and a rotation map for SC and IM injections across TRT, GLP-1, and peptides.
Why a "normal" total testosterone result can still mean low free T, how SHBG distorts the picture, and the Vermeulen calculation your lab probably isn't running for you.
Why testosterone cypionate takes 4–5 weeks to reach steady state, what your bloodwork actually shows after one shot, and how to time labs for an accurate trough.
Semaglutide has a 7-day half-life — meaning measurable plasma concentration weeks after stopping. What that means for missed doses, breaks, and switching protocols.
A clinician-grade walkthrough of the BAC water → mg/mL → insulin units math, with worked examples for BPC-157, Ipamorelin, HGH, and CJC-1295.
More guides coming. Have a topic request? hello@dosetrack.app